Welcome to Roche Foundation Medicine.

This site is not intended to provide medical advice and/or treatment guidance. It is produced by Roche as a partner of Foundation Medicine.

Please select an option:

Roche launches FoundationOne CDx genomic profiling assay in Singapore

November 22, 2018

By the Editorial Team, Compelo, 23 November 2018

Multinational healthcare firm Roche has introduced FoundationOne CDx genomic profiling assay in Singapore to guide personalized treatment decisions.

FoundationOne CDx, which is Foundation Medicine’s comprehensive companion diagnostic test, will support clinicians in better decision-making.

It provides clear and in-depth report that presents the unique genomic profile of a patient’s tumor, as well as associated and approved therapies and relevant clinical trials.

FoundationOne CDx is the progression of FoundationOne, which is Foundation Medicine’s original laboratory-developed genomic profiling test.

The US Food and Drug Administration has assessed and approved FoundationOne CDx platform, comprising analytical and clinical validation, and bioinformatics.

OncoCare Cancer Centre senior consultant medical oncologist Tay Miah Hiang said: “The biggest advantage of next generation sequencing is that it can capture all the essential cancer biomarkers to help clinicians select the right therapy for patients in a single testing attempt, particularly when tumour samples are limited.”

FoundationOne CDx is comprised of an updated gene list, including all major classes of genomic alterations in 324 of the most commonly mutated genes that enhance the growth of cancer. The companion diagnostic test also allows to detect tumor mutational burden (TMB) and microsatellite instability and genomic signatures, which are helpful in taking cancer immunotherapy-based treatment decisions.

National Cancer Centre Singapore medical oncology division senior consultant and assistant professor Dr Ravindran Kanesvaran said: “Upfront testing of TMB and additional biomarkers are beneficial to physicians, as they would have more information to guide their treatment selection and the patient would have access to more treatment options.”

In September this year, Roche announced the global availability of blood-based genomic profiling test, FoundationOne Liquid, which can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability.

FoundationOne Liquid can identify circulating tumour DNA in the blood of people living with cancer. It can also identify 70 of the most commonly mutated genes in solid tumours, including microsatellite instability.